Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Clin Cancer Res. 2017 Sep 12;23(23):7324–7332. doi: 10.1158/1078-0432.CCR-17-1561

Figure 4. TMEM16A contributes to in vivo cisplatin resistance.

Figure 4

A: OSC19 TMEM16A overexpressing (TMEM16A) tumor xenografts (n = 10) were significantly larger than control tumor xenografts (n = 11) and were not affected by treatment with cisplatin. Cisplatin treatment initiated at arrowhead. B & C: OSC19 TMEM16A overexpressing tumors experienced significantly less apoptosis as shown by reduced TUNEL staining on IHC section. All data expressed as mean ± SEM relative to control conditions, unless otherwise noted; *p < .05, **p < .01, ****p< .0001.